ECALTA, known generically as anidulafungin, is a member of the echinocandin class of antifungal medications. It is specifically designed to combat a variety of fungal infections, particularly those caused by Candida species, including infections that are systemic or invasive. ECALTA works by inhibiting the synthesis of glucan, a crucial component of the fungal cell wall, thereby disrupting the integrity of the cell wall and leading to the death of the fungal cells. Administered intravenously, it is often reserved for patients who are critically ill or have not responded to other antifungal treatments. ECALTA is recognized for its efficacy in treating serious fungal infections and is a valuable option in the medical management of resistant fungal pathogens.